Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSV mRNA vaccine (Changchun BCHT Pharmaceutical)
- Development stage
- Preclinical
- Lead developer
- CureVac
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
RSV mRNA vaccine (Changchun BCHT Pharmaceutical) is an investigational messenger RNA (mRNA) vaccine candidate designed for the prevention of respiratory syncytial virus (RSV) infection. Developed by Changchun BCHT Pharmaceutical, often in strategic collaboration with CureVac, the vaccine utilizes an mRNA platform to instruct host cells to express RSV-specific antigens, typically the fusion (F) protein. This expression triggers the immune system to produce neutralizing antibodies and activate T-cell responses, providing prophylactic protection against RSV-associated lower respiratory tract disease. The candidate is currently in the preclinical stage of development and aims to address the significant global health burden of RSV, particularly in high-risk populations such as infants and the elderly.
- Other names
- RSV mRNA疫苗respiratory syncytial virus mRNA vaccine
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on RSV mRNA vaccine (Changchun BCHT Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSV mRNA vaccine (Changchun BCHT Pharmaceutical).